<DOC>
	<DOC>NCT01037179</DOC>
	<brief_summary>The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.</brief_summary>
	<brief_title>An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subjects must provide written consent. Subjects must have a diagnosis of allergic conjunctivitis. Other protocoldefined inclusion criteria may apply. Itching and/or hyperemia associated with diseases other than allergic conjunctivitis. Retinal detachment, diabetic retinopathy, or any progressive disease in posterior segment of the eye. Known history of ocular infection. Contact lens wear during study. Pregnant, nursing. Participation in another clinical study within 30 days of Informed Consent. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>